BioSpace

Should amylin have been obesity therapeutics’ primary target from the start?

While GLP-1 medicines have become synonymous with weight loss, at least one expert thinks amylin would have been the go-to target if biopharma had been focused on the blockbuster indication 10 years ago. A new wave of therapies is now exploring this potentially gentler mechanism.

By BioSpace

1 min read
Should amylin have been obesity therapeutics’ primary target from the start?
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights